Comparison of the effect of Erythropoietin, L-Carnitine and Erythropoietin plus L-Carnitine in correction of anemia in chronic haemodialysis patients
| ISRCTN | ISRCTN96315193 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN96315193 |
| Protocol serial number | N/A |
| Sponsor | Tabriz University of Medical Sciences (Iran) |
| Funder | Tabriz University of Medical Sciences (Iran) |
- Submission date
- 07/08/2005
- Registration date
- 11/08/2005
- Last edited
- 25/09/2009
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Urological and Genital Diseases
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year
Plain English summary of protocol
Not provided at time of registration
Contact information
Dr Hamid Tayebi Khosroshahi
Scientific
Scientific
Dialysis Center
Imam Hospital
Daneshgah Street
Tabriz
Iran
| Phone | +98 411 3344339 |
|---|---|
| drtayebikh@yahoo.com |
Study information
| Primary study design | Interventional |
|---|---|
| Study design | Randomised controlled trial |
| Secondary study design | Randomised controlled trial |
| Scientific title | |
| Study acronym | Carnitine-Epo |
| Study objectives | Anemia in chronic haemodialysis patients is improved by administration of Erythropoietin or L-Carnitine or Erythropoietin plus L-Carnitine. |
| Ethics approval(s) | Not provided at time of registration |
| Health condition(s) or problem(s) studied | Chronic Renal Failure (End-Stage Renal Disease [ESRD]) |
| Intervention | 1. Administration of rHu-EPO 4000 IU/week, subcutaneously (SC) (2000 IU, twice weekly) for 3 months (N = 20) 2. Administration of L-Carnitine 500 mg/day, orally, for 3 months (N = 15) 3. Administration of rHu-EPO 4000 IU/week, SC PLUS L-Carnitine 500 mg/day, orally, for 3 months (N = 15) |
| Intervention type | Drug |
| Phase | Not Specified |
| Drug / device / biological / vaccine name(s) | Erythropoietin, L-Carnitine |
| Primary outcome measure(s) |
Haemoglobin level |
| Key secondary outcome measure(s) |
Not provided at time of registration |
| Completion date | 01/03/2005 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Adult |
| Sex | All |
| Target sample size at registration | 50 |
| Key inclusion criteria | 1. Dialysis for more than 6 months 2. Hb less than 11 g/dl |
| Key exclusion criteria | 1. Active infectious disease 2. Active bleeding disorders |
| Date of first enrolment | 01/03/2003 |
| Date of final enrolment | 01/03/2005 |
Locations
Countries of recruitment
- Iran
Study participating centre
Dialysis Center
Tabriz
Iran
Iran
Results and Publications
| Individual participant data (IPD) Intention to share | No |
|---|---|
| IPD sharing plan summary | Not provided at time of registration |
| IPD sharing plan |
